癌症基因组图谱转录组 TIL 免疫特征的全癌种比较分析

英文原题：A Pan-Cancer Comparative Analysis of The Cancer Genome Atlas Transcriptomic TIL-Immune Signatures.

查看英文原题

A Pan-Cancer Comparative Analysis of The Cancer Genome Atlas Transcriptomic TIL-Immune Signatures.

PubMed 2025/04/25（内容时间） Res Sq

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

通过基础科学研究和癌症基因组图谱（TCGA）数据分析理解肿瘤微环境（TME）的努力，促成了基于TIL（肿瘤浸润淋巴细胞）构建独特免疫转录组特征。然而，尚无泛癌分析使用总生存期（OS）或无进展间期（PFI）作为终点，比较这些特征的预后表现。我们汇总了146种TIL免疫特征，并评估其基因特征评分与33种癌症类型中9,961份可用TCGA样本的OS和PFI之间的相关性。Zhang CD8 TCS在泛癌范围内预测OS和PFI的准确性均较高，但不同癌症类型及生殖细胞来源之间存在差异。聚类分析筛选出由六种特征组成的一组（Oh.Cd8.MAIT、Grog.8KLRB1、Oh.TIL_CD4.GZMK、Grog.CD4.TCF7、Oh.CD8.RPL、Grog.CD4.RPL32），这些特征与OS和PFI的关联可能在多种癌症类型中保持一致。

展开英文摘要原文

Efforts to understand the tumor microenvironment (TME) through basic science research and The Cancer Genome Atlas (TCGA) data analysis have led to the creation of unique immune transcriptomic signatures from tumor-infiltrating lymphocytes (TIL).

However, no pan-cancer analysis has been conducted to compare the prognostic performance of these signatures using overall survival (OS) or progression-free interval (PFI) as endpoints.

We compiled a library of 146 TIL-immune signatures and evaluated gene signature score correlation with OS and PFI for 9,961 available TCGA samples across 33 cancer types. Zhang CD8 TCS demonstrated higher accuracy in prognosticating both OS and PFI across the pan-cancer landscape, however, variability was seen across cancer types and germ cell origin.

Cluster analysis compiled a group of six signatures (Oh. Cd8. MAIT, Grog. 8KLRB1, Oh. TIL_CD4. GZMK, Grog. CD4. TCF7, Oh. CD8. RPL, Grog. CD4. RPL32) whose association with OS and PFI could potentially be conserved across multiple cancer types.

论文信息

作者: Hitscherich K、Noussome D、Dinerman A、Dulemba V、Lowery F、Nilubol N
单位: National Cancer Institute.
文献类型: 预印本
期刊: Research square2025 Apr 25

原文标识: PubMed 40313762　·　DOI 10.21203/rs.3.rs-6441170/v1

在 PubMed 查看 → 出版商原文（DOI）治疗专题与资料阅读指南资料来源与翻译说明报告译文或资料问题 →